ReviewParasite (Paris, France)2011
Pneumocystis jirovecii pneumonia in developing countries.
Review in Parasite (Paris, France), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global prevalence, mortality, and main characteristics of HIV-associated pneumocystosis: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis.BMC infectious diseases · 2016Pooled it
- Past Achievements, Present Gaps, and Future Priorities in Pneumocystis jirovecii Research: A Global Bibliometric Analysis.Pathogens (Basel, Switzerland) · 2026Review
- Helminth Immune Modulation and Invasive Fungal Infections in Sub-Saharan Africa.Journal of fungi (Basel, Switzerland) · 2026Article
- Molecular Study ofJournal of fungi (Basel, Switzerland) · 2024Article
- Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives.Journal of fungi (Basel, Switzerland) · 2023Review
- Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy.Neuro-oncology · 2022Article
- Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.BMC infectious diseases · 2022Article
- Prevalence of Pneumocystosis in Sub-Saharan Africa and Helminth Immune Modulation.Journal of fungi (Basel, Switzerland) · 2021Article
- Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago.IJID regions · 2021Article
- On the Treatment ofOpen forum infectious diseases · 2021Review
- Update on Dihydropteroate Synthase (DHPS) Mutations inJournal of fungi (Basel, Switzerland) · 2021Review
- COVID-19 andMedicina (Kaunas, Lithuania) · 2021Article
- Review
- The Burden of Fungal Infections in Ethiopia.Journal of fungi (Basel, Switzerland) · 2019Review
- The Contribution of Host Cells toPathogens (Basel, Switzerland) · 2019Review
- Changing Trends in the Epidemiology and Risk Factors ofFrontiers in public health · 2019Article
- Absence of dihydropteroate synthase gene mutations in Pneumocystis jirovecii strains isolated from Aegean region of Turkey.Parasitology research · 2018Article
- Article
- Estimated Burden of Serious Fungal Infections in Mozambique.Journal of fungi (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumocystis pneumonia (PcP) is a serious fungal infection among immunocompromised patients. In developed countries, the epidemiology and clinical spectrum of PcP have been clearly defined and well documented. However, in most developing countries, relatively little is known about the prevalence of pneumocystosis. Several articles covering African, Asian and American countries were reviewed in the present study. PcP was identified as a frequent opportunistic infection in AIDS patients from different geographic regions. A trend to an increasing rate of PcP was apparent in developing countries from 2002 to 2010.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.